Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

NRX Pharmaceuticals Inc

NRXP
Current price
1.39 USD +0.025 USD (+1.82%)
Last closed 1.37 USD
ISIN US6294441000
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 13 006 895 USD
Yield for 12 month -57.72 %
1Y
3Y
5Y
10Y
15Y
NRXP
21.11.2021 - 28.11.2021

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. Address: 1201 Orange Street, Wilmington, DE, United States, 19801

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

31.33 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+8 000 USD

Current Year

-5 000 USD

Last Year

-4 000 USD

Current Quarter

-1 000 USD

Last Quarter

-1 000 USD

Key Figures NRXP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -23 257 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -115.97 %
PEG Ratio
Return On Equity TTM -682.61 %
Wall Street Target Price 31.33 USD
Revenue TTM
Book Value -1.72 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.68 USD
Diluted Eps TTM -2.68 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics NRXP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History NRXP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 02.04.2024
Dividend Date

Stock Valuation NRXP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.1511
Price Book MRQ 2.9042

Financials NRXP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators NRXP

For 52 weeks

1.1 USD 7.33 USD
50 Day MA 1.6 USD
Shares Short Prior Month 532 088
200 Day MA 3.14 USD
Short Ratio 7.36
Shares Short 566 989
Short Percent 6.39 %